Ultragenyx Pharmaceutical (RARE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Ultragenyx Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$560.23M

Latest Revenue (Q)

$166.50M

Main Segment (Y)

Product

Main Geography (Y)

North America

Ultragenyx Pharmaceutical Revenue by Period

Ultragenyx Pharmaceutical Revenue by Year

Date	Revenue	Change
2024-12-31	$560.23M	29.01%
2023-12-31	$434.25M	19.52%
2022-12-31	$363.33M	3.39%
2021-12-31	$351.41M	29.66%
2020-12-31	$271.03M	161.32%
2019-12-31	$103.71M	101.41%
2018-12-31	$51.49M	1871.48%
2017-12-31	$2.61M	1863.91%
2016-12-31	$133.00K	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	-

Ultragenyx Pharmaceutical generated $560.23M in revenue during NA 2024, up 29.01% compared to the previous quarter, and up 540.17% compared to the same period a year ago.

Ultragenyx Pharmaceutical Revenue by Quarter

Date	Revenue	Change
2025-06-30	$166.50M	19.53%
2025-03-31	$139.29M	-15.52%
2024-12-31	$164.88M	18.20%
2024-09-30	$139.49M	-5.12%
2024-06-30	$147.03M	35.09%
2024-03-31	$108.83M	-14.57%
2023-12-31	$127.39M	29.92%
2023-09-30	$98.05M	-9.47%
2023-06-30	$108.31M	7.77%
2023-03-31	$100.50M	-2.76%
2022-12-31	$103.35M	13.94%
2022-09-30	$90.70M	1.52%
2022-06-30	$89.34M	11.77%
2022-03-31	$79.94M	-4.14%
2021-12-31	$83.39M	2.13%
2021-09-30	$81.65M	-6.13%
2021-06-30	$86.97M	-12.50%
2021-03-31	$99.39M	8.58%
2020-12-31	$91.54M	12.36%
2020-09-30	$81.47M	32.02%
2020-06-30	$61.71M	69.96%
2020-03-31	$36.31M	2.01%
2019-12-31	$35.59M	37.96%
2019-09-30	$25.80M	6.84%
2019-06-30	$24.15M	32.89%
2019-03-31	$18.17M	11.75%
2018-12-31	$16.26M	38.24%
2018-09-30	$11.76M	-8.06%
2018-06-30	$12.79M	19.83%
2018-03-31	$10.68M	342.29%
2017-12-31	$2.41M	1119.19%
2017-09-30	$198.00K	100.00%
2017-06-30	-	100.00%
2017-03-31	-	-100.00%
2016-12-31	$5.00K	-95.50%
2016-09-30	$111.00K	552.94%
2016-06-30	$17.00K	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	-

Ultragenyx Pharmaceutical generated $166.50M in revenue during Q2 2025, up 19.53% compared to the previous quarter, and up 152.98% compared to the same period a year ago.

Ultragenyx Pharmaceutical Revenue Breakdown

Ultragenyx Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Product	$285.42M	$180.41M	-	-	-
Royalty	$274.81M	$182.65M	-	-	-
Collaboration And License	-	$71.18M	$7.69M	$85.00M	$89.22M

Ultragenyx Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (50.95%), and Royalty (49.05%).

Quarterly Revenue by Product

Product/Service	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Royalty	$85.68M	$47.78M	$93.01M	$62.24M	$73.22M	$46.34M	$126.95M	$55.70M	-	-	-	-	-	-	-	-	-	-	-	-
Product	$80.82M	$91.51M	$71.87M	$77.25M	$73.81M	$62.49M	$138.06M	$42.35M	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration And License	-	-	-	-	-	-	$69.70M	$1.48M	$1.48M	$1.48M	$1.48M	$3.25M	$8.23M	$12.06M	$21.96M	$42.75M	$37.50M	$32.87M	$18.86M	-

Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Royalty (51.46%), and Product (48.54%).

Ultragenyx Pharmaceutical Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Latin America	$130.71M	$77.34M	$44.71M	-	-
North America	$340.46M	$307.15M	$281.09M	$301.11M	$237.67M
Asia Pacific	$8.93M	-	-	-	-
EMEA	$80.12M	-	-	-	-
Europe	-	$47.53M	$36.37M	$26.66M	$21.32M
JAPAN	-	$2.22M	$1.16M	-	-
All Other	-	-	-	$23.64M	$12.05M

Ultragenyx Pharmaceutical's latest annual revenue breakdown by geography, as of Dec 24: North America (60.77%), Latin America (23.33%), EMEA (14.30%), and Asia Pacific (1.59%).

Quarterly Revenue by Country

Country	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
North America	$102.93M	$57.79M	$116.98M	$76.91M	$88.89M	$57.68M	$92.92M	$67.81M	$79.29M	$67.13M	$70.89M	$66.91M	$75.57M	$87.74M	$82.73M	$72.65M	-	-	-	-
Asia Pacific	$4.20M	$3.29M	$3.57M	$2.31M	$3.05M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Latin America	$32.97M	$54.89M	$18.56M	$38.05M	$38.93M	$35.18M	$18.25M	$17.23M	$19.07M	$22.80M	$8.26M	$14.12M	$12.54M	$9.79M	$7.49M	$4.71M	-	-	-	-
EMEA	$26.40M	$23.33M	$41.74M	$22.22M	$16.16M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Europe	-	$23.33M	$15.97M	$15.18M	$13.01M	$9.95M	$9.39M	$10.26M	$8.41M	$9.48M	$8.23M	$7.08M	$7.24M	$6.70M	$5.64M	$5.61M	$5.00M	-	-	-
JAPAN	-	-	-	-	-	-	$1.05M	-	-	$1.18M	-	$1.16M	-	-	-	-	-	-	-	-
U.S. and Canada	-	-	-	-	-	-	-	-	-	-	-	$67.01M	$67.33M	$61.92M	-	-	-	-	-	-
All Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.02M	$3.20M	$3.82M

Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by geography, as of Jun 25: North America (61.82%), Latin America (19.80%), EMEA (15.86%), and Asia Pacific (2.52%).

Ultragenyx Pharmaceutical Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BMRN	BioMarin Pharmaceutical	$2.85B	$825.41M
PTCT	PTC Therapeutics	$806.78M	$1.18B
RARE	Ultragenyx Pharmaceutical	$560.23M	$166.50M
BPMC	Blueprint Medicines	$508.82M	$149.41M
DAWN	Day One Biopharmaceuticals	$131.16M	$33.91M
AGIO	Agios Pharmaceuticals	$36.50M	$12.46M
QURE	uniQure	$27.12M	$5.26M
MREO	Mereo BioPharma Group	-	-

RARE Revenue FAQ

What is Ultragenyx Pharmaceutical’s yearly revenue?

Ultragenyx Pharmaceutical's yearly revenue for 2024 was $560.23M, representing an increase of 29.01% compared to 2023. The company's yearly revenue for 2023 was $434.25M, representing an increase of 19.52% compared to 2022. RARE's yearly revenue for 2022 was $363.33M, representing an increase of 3.39% compared to 2021.

What is Ultragenyx Pharmaceutical’s quarterly revenue?

Ultragenyx Pharmaceutical's quarterly revenue for Q2 2025 was $166.5M, a 19.53% increase from the previous quarter (Q1 2025), and a 13.24% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $139.29M, a -15.52% decrease from the previous quarter (Q4 2024), and a 27.99% increase year-over-year (Q1 2024). RARE's quarterly revenue for Q4 2024 was $164.88M, a 18.20% increase from the previous quarter (Q3 2024), and a 29.42% increase year-over-year (Q4 2023).

What is Ultragenyx Pharmaceutical’s revenue growth rate?

Ultragenyx Pharmaceutical's revenue growth rate for the last 3 years (2022-2024) was 54.19%, and for the last 5 years (2020-2024) was 106.70%.

What are Ultragenyx Pharmaceutical’s revenue streams?

Ultragenyx Pharmaceutical's revenue streams in c 24 are Product, and Royalty. Product generated $285.42M in revenue, accounting 50.95% of the company's total revenue, up 58.20% year-over-year. Royalty generated $274.82M in revenue, accounting 49.05% of the company's total revenue, up 50.46% year-over-year.

What is Ultragenyx Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Ultragenyx Pharmaceutical was Product. This segment made a revenue of $285.42M, representing 50.95% of the company's total revenue.